Physician profile
Amy C Smith
NPI 1972547362
$3,501.85
in general payments reported to CMS, 2019-2025
32 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $505 · 2023: $1,098 · 2024: $479 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $778.50 | 2021-2025 | |
| Janssen Biotech, INC. | $514.84 | 2022-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $294.20 | 2021-2025 | |
| Qol Medical, LLC | $225.78 | 2021-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $221.24 | 2021-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.54 | 2021-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $168.89 | 2024-2025 | Voquezna |
| Genzyme Corporation | $132.37 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $125.71 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $101.81 | 2021-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $84.68 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $65.57 | 2023 | Stelara |
| Celgene Corporation | $64.80 | 2023-2024 | Zeposia |
| Vanda Pharmaceuticals INC. | $64.77 | 2022-2023 | Fanapt, Hetlioz |
| Novo Nordisk INC | $47.76 | 2025 | Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $41.61 | 2023 | |
| Corium, LLC | $35.70 | 2023 | Azstarys |
| Enterra Medical, INC. | $31.12 | 2023 | |
| Axonics, INC. | $30.26 | 2022-2023 | Axonics |
| Cardiva Medical, INC. | $27.00 | 2023 | Cardiva Vascade 6/7f Vcs |
| Abbott Laboratories | $24.88 | 2025 | Eterna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.83 | 2021 | |
| Sun Pharmaceutical Industries INC. | $22.24 | 2022 | |
| Redhill Biopharma INC. | $22.18 | 2021 | |
| Amgen INC. | $21.03 | 2021 | |
| Intercept Pharmaceuticals, INC. | $19.12 | 2025 | |
| Celltrion USA INC. | $18.88 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $18.63 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $17.68 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $16.46 | 2025 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $16.11 | 2022 | |
| Clarus Therapeutics INC. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.